Stock Track | Myriad Genetics Tumbles 7.69% After-Hours on Disappointing Q4 Earnings and Executive Transition

Stock Track

02-25

Myriad Genetics (MYGN) stock plunged 7.69% in the after-hours trading session on Monday, following its fourth-quarter earnings report and the announcement of a senior leadership transition.

Firstly, the company reported mixed financial results for the fourth quarter. While total revenue increased 7.12% year-over-year to $210.6 million, it missed analyst estimates of $211.62 million. Additionally, adjusted earnings per share of $0.03 met expectations but declined by 25% compared to the same period last year.

Furthermore, Myriad Genetics announced that its President and CEO, Paul J. Diaz, will step down on April 30, 2025, to join private equity firm Cressey & Company as a Managing Partner. The company has appointed its current Chief Operating Officer, Sam Raha, as the new President and CEO, effective April 30. Raha has been with Myriad since December 2023 and was previously the President of Agilent's Diagnostics and Genomics Group. Mark S. Verratti, the current Chief Commercial Officer, will be promoted to Chief Operating Officer.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1109581245"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1109581245\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1109581245?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-25 05:36","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1109581245","market":"hk","top_or_hot":-1,"title":"Stock Track | Myriad Genetics Tumbles 7.69% After-Hours on Disappointing Q4 Earnings and Executive Transition","media":"Stock Track","content":"<p>Myriad Genetics (MYGN) stock plunged 7.69% in the after-hours trading session on Monday, following its fourth-quarter earnings report and the announcement of a senior leadership transition.</p>\n\n<p>Firstly, the company reported mixed financial results for the fourth quarter. While total revenue increased 7.12% year-over-year to $210.6 million, it missed analyst estimates of $211.62 million. Additionally, adjusted earnings per share of $0.03 met expectations but declined by 25% compared to the same period last year.</p>\n\n<p>Furthermore, Myriad Genetics announced that its President and CEO, Paul J. Diaz, will step down on April 30, 2025, to join private equity firm Cressey & Company as a Managing Partner. The company has appointed its current Chief Operating Officer, Sam Raha, as the new President and CEO, effective April 30. Raha has been with Myriad since December 2023 and was previously the President of Agilent's Diagnostics and Genomics Group. Mark S. Verratti, the current Chief Commercial Officer, will be promoted to Chief Operating Officer.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Myriad Genetics Tumbles 7.69% After-Hours on Disappointing Q4 Earnings and Executive Transition</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Myriad Genetics Tumbles 7.69% After-Hours on Disappointing Q4 Earnings and Executive Transition\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time smaller\">2025-02-25 05:36</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>Myriad Genetics (MYGN) stock plunged 7.69% in the after-hours trading session on Monday, following its fourth-quarter earnings report and the announcement of a senior leadership transition.</p>\n\n<p>Firstly, the company reported mixed financial results for the fourth quarter. While total revenue increased 7.12% year-over-year to $210.6 million, it missed analyst estimates of $211.62 million. Additionally, adjusted earnings per share of $0.03 met expectations but declined by 25% compared to the same period last year.</p>\n\n<p>Furthermore, Myriad Genetics announced that its President and CEO, Paul J. Diaz, will step down on April 30, 2025, to join private equity firm Cressey & Company as a Managing Partner. The company has appointed its current Chief Operating Officer, Sam Raha, as the new President and CEO, effective April 30. Raha has been with Myriad since December 2023 and was previously the President of Agilent's Diagnostics and Genomics Group. Mark S. Verratti, the current Chief Commercial Officer, will be promoted to Chief Operating Officer.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"MYGN","symbol_name":"萬基遺傳","start_time":0,"source_url":"","article_id":"1109581245","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1109581245","pubTimestamp":1740433012,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Myriad Genetics  stock plunged 7.69% in the after-hours trading session on Monday, following its fourth-quarter earnings report and the announcement of a senior leadership transition.Firstly, the company reported mixed financial results for the fourth quarter. While total revenue increased 7.12% year-over-year to $210.6 million, it missed analyst estimates of $211.62 million. Additionally, adjusted earnings per share of $0.03 met expectations but declined by 25% compared to the same period last ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"MYGN":"万基遗传"},"translate_title":"由于第四季度盈利和高管交接令人失望，Myriad Genetics盘后下跌7.69%","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MYGN":1},"content_text":"Myriad Genetics (MYGN) stock plunged 7.69% in the after-hours trading session on Monday, following its fourth-quarter earnings report and the announcement of a senior leadership transition.\nFirstly, the company reported mixed financial results for the fourth quarter. While total revenue increased 7.12% year-over-year to $210.6 million, it missed analyst estimates of $211.62 million. Additionally, adjusted earnings per share of $0.03 met expectations but declined by 25% compared to the same period last year.\nFurthermore, Myriad Genetics announced that its President and CEO, Paul J. Diaz, will step down on April 30, 2025, to join private equity firm Cressey & Company as a Managing Partner. The company has appointed its current Chief Operating Officer, Sam Raha, as the new President and CEO, effective April 30. Raha has been with Myriad since December 2023 and was previously the President of Agilent's Diagnostics and Genomics Group. Mark S. Verratti, the current Chief Commercial Officer, will be promoted to Chief Operating Officer.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1}}}